Seres reports 80% immunosuppressive-free clinical response for SER-155 in irEC trial

Seres Therapeutics, Inc.

12 of 15 patients (80%) achieved primary endpoint: ≥1-grade diarrhea improvement without immunosuppressives at Day 15.
5 of 15 (33%) achieved complete remission (Grade 0 diarrhea) at Day 15; 2 of 15 (13%) maintained at Day 43.
SER-155 well tolerated; no drug-related serious adverse events or bloodstream infections through Day 43.
Biomarkers (fecal calprotectin, albumin) showed statistically significant reductions at Day 43, indicating reduced GI inflammation.
Company engaging with potential partners for SER-155 development in irEC and seeking funding for allo-HCT Phase 2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.